Company Profile (AI Text)
Name: 20/20 GeneSystems
Canonical URL: https://wefunder.com/2020.gene.systems
Updated at: 2026-06-17T05:02:46Z

Tagline: Biomarker Testing for Multi-Cancer Early Detection and Longevity

Key claims:
- Total raised on Wefunder: 542161 | citation: https://wefunder.com/2020.gene.systems#claim-total-raised
- Total investors: 360 | citation: https://wefunder.com/2020.gene.systems#claim-total-investors

Verified facts:
- Total raised on Wefunder: 542161 | observed_at: 2026-06-17T05:02:46Z | expires_at: 2026-06-18T05:02:46Z
- Total investors: 360 | observed_at: 2026-06-17T05:02:46Z | expires_at: 2026-06-18T05:02:46Z

Computed metrics:
- total_amount_raised: 542161
- total_investors: 360
- team_size: 6
- featured_investor_count: 1
- faq_count: 5
- recent_post_count: 1

Quick facts:
- 20/20 is a leader in the Multi-Cancer Early Detection (MCED) market, expected to reach $50B. | citation: https://wefunder.com/2020.gene.systems#claim-fact-1
- VC investments: Wako (Fujifilm), PingAn, Calvert (Morgan Stanley), MD Venture Fund, Brevet, Keiretsu | citation: https://wefunder.com/2020.gene.systems#claim-fact-2
- Secured $5M+ in research grants/contracts from National Cancer Institute (NCI) and others. | citation: https://wefunder.com/2020.gene.systems#claim-fact-3
- Ranked #134 on 2023 Inc. 5000 list of the “Fastest Growing Companies in America” (#1 in Maryland). | citation: https://wefunder.com/2020.gene.systems#claim-fact-4
- Utilize technology from Abbott Diagnostics and Roche Diagnostics for our MCED solutions. | citation: https://wefunder.com/2020.gene.systems#claim-fact-5
- Sales volume from our cancer testing grew 2.2X from 2022 to 2023. | citation: https://wefunder.com/2020.gene.systems#claim-fact-6
- Multiple issued or allowed patents in the U.S. and East Asia (available in Downloads section). | citation: https://wefunder.com/2020.gene.systems#claim-fact-7
- Our team has 100+ years of combined biotech/life science experience. Board chair sold BioDx to Opko. | citation: https://wefunder.com/2020.gene.systems#claim-fact-8

FAQ:
- Q: What prior equity raises have you done? How have the price/valuation changed? Any splits along the way?
  A: The Company has raised $27.6M in equity since its inception in 2000. Approximately $16.5M has been raised over the past 10 years through crowdfunding and the pre-money valuations/pricing have increased as follows: 2014 $15M/$3.07ps; 2016 $20.8M/$3.26ps; 2017 $24M/$3.53ps; 2019 $37.8M/$4.40; $58M/$4.95ps; $70M/$5.34ps on this current round. There have been no splits or recapitalizations along the way.
- Q: Good day there have been previous raises 2017 Microventures at $3.26 per share and 2020 StartEngine at $4.40 per share; what is $ per share for this raise and why the changes in funding platforms? Thanks Rob
  A: The $ per share pricing for this round is $5.34/share. Our last round of funding with StartEngine was not provided the same level of customer service that we were accustomed to in our previous rounds. Perhaps due to their rapid growth over the past few years we are not sure but where they would assign a campaign representative they shifted to a general e-mail for customer service support. We had heard good things about WeFunder and decided to try a different platform that would provide a camp...
- Q: Hi Anne, I've been a shareholder since 2018 😊. I would like to invest again, but am a bit perplexed at the high minimum investment amount you’ve set. Why so high? Please consider the limitations placed on Non-accredited investors (read 'small investors') by the SEC . If I make...
  A: We are looking at this and will get back to you on whether we can lower our minimum.
- Q: Are you able to share what your 2023 revenue was? Profitability?
  A: 2023 Revenue total was $1.4M and our net loss was $6.5M. We anticipate losses into 2025 as we invest in research and development activities and increase spending to expand our sales and marketing efforts to penetrate new and existing markets and launch new products.
- Q: Being in healthcare, I love the concept of this company. Companies like this can transform healthcare in the future. My hesitation are your financials/being a tough financing environment right now. What is your path to sustain through your losses this year and next year and to...
  A: Adam, great question, we are actively raising money both in crowdfunding and through institutional investors, and we manage our cash flow closely. As you probably know from being in healthcare, many life science companies operate at a loss in the early years from the creation of the products to launching the products and many years after that; look at Grail who is our biggest competitor (they are still in the red due to heavy marketing & R&D). We will continue to operate lean with a f...

Recent posts:
- Wefunder Discover Recording - 20/20 GeneSystems (2024-12-11T19:35:14Z) https://wefunder.com/feed/178149